Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Human fibrinogen concentrate - CSL Behring

Next Previous
Search
Drug Profile

Human fibrinogen concentrate - CSL Behring

Alternative Names: CSL-511; Fibrinogen Concentrate (Human); Haemocomplettan P; RiaSTAP

Latest Information Update: 26 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CSL Behring
  • Developer CSL Behring; Rigshospitalet
  • Class Acute-phase proteins; Antihaemorrhagics; Blood coagulation factors; Coagulants
  • Mechanism of Action Fibrinogen replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Afibrinogenaemia
  • New Molecular Entity No

Highest Development Phases

  • Marketed Afibrinogenaemia
  • Phase III Pseudomyxoma peritonei; Surgical blood loss
  • Phase II Haemorrhage

Most Recent Events

  • 01 Oct 2024 Phase-III clinical trials in Pseudomyxoma-peritonei in United Kingdom (IV) (NCT06617897)
  • 30 Sep 2024 CSL Behring plans phase-III trial for Pseudomyxoma Peritonei in September 2024 (IV, infusion) (NCT06617897)
  • 28 Nov 2018 No recent reports of development identified for clinical-Phase-Unknown development in Haemorrhage(Adjunctive treatment) in United Kingdom (IV, Infusion)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top